Catégorie : Dossiers scientifiques

The Effects of Cannabinoids on Sleep, Bhanu Prakash Kolla et al., 2022

The Effects of Cannabinoids on Sleep Bhanu Prakash Kolla, Lisa Hayes, Chaun Cox, Lindy Eatwell, Mark Deyo-Svendsen , and Meghna P. Mansukhani Journal of Primary Care & Community Health, 2022, Volume 13, 1–9. Doi : 10.1177/21501319221081277 Abstract The use of cannabis products to help with sleep and various other medical conditions by the public has increased significantly in recent years. Withdrawal from cannabinoids can lead to sleep disturbance. Here, we describe a patient who developed significant insomnia leading to worsening anxiety, mood, and suicidal ideation in the setting of medical cannabis withdrawal, prompting presentation to the Emergency Department and inpatient admission. There is a limited [...]

Lire la suite

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects, Friederike Holze et al., 2022

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Friederike Holze, Laura Ley, Felix Müller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sebastian Silva Kuehne, Marc A. Roder, Urs Duthaler, Karolina E. Kolaczynska, Nimmy Varghese, Anne Eckert and Matthias E. Liechti Neuropsychopharmacology, 2022, 1-8. Doi : 10.1038/s41386-022-01297-2 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double blind, randomized, placebo-controlled, [...]

Lire la suite

Contaminants of Concern in Cannabis : Microbes, Heavy Metals and Pesticides John M. McPartland and Kevin J. McKernan, 2017

Contaminants of Concern in Cannabis : Microbes, Heavy Metals and Pesticides John M. McPartland and Kevin J. McKernan in S. Chandra et al. (eds.), Cannabis sativa L. - Botany and Biotechnology, Chapter 22, 2017, 457-474. Doi : 10.1007/978-3-319-54564-6_22 Abstract Microbiological contaminants pose a potential threat to cannabis consumers. Bacteria and fungi may cause opportunistic infections in immuno-compromized individuals. Even dead organisms may trigger allergies and asthma. Toxins from microbial overloads, such as Shigla toxin and aflatoxins, may pose a problem—unlikely, but possible. The Cannabis plant hosts a robust microbiome; the identification of these organisms is underway. Cannabis bioaccumulates heavy metals in its tissues, so avidly [...]

Lire la suite

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder : Prospective 12-month follow-up, Natalie Gukasyan et al., 2022

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder : Prospective 12-month follow-up Natalie Gukasyan, Alan K Davis, Frederick S Barrett, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson and Roland R Griffiths Journal of Psychopharmacology, 2022, Vol. 36(2) 151–158. Doi : 10.1177/02698811211073759   Abstract Background : Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims : This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods : This randomized, waiting-list controlled study [...]

Lire la suite

Genomic and Chemical Diversity in Cannabis, C. Lynch et al., 2015

Genomic and Chemical Diversity in Cannabis Ryan C. Lyncha,e, Daniela Vergaraa, Silas Tittesa, Kristin Whitea, C. J. Schwartzb, Matthew J. Gibbsb, Travis C. Ruthenburgc,d, Kymron deCesarec, Donald P. Landc, and Nolan C. Kanea CRITICAL REVIEWS IN PLANT SCIENCES, 2016, VOL. 35, NOS. 5–6, 349–363 Doi : 10.1080/07352689.2016.1265363 ABSTRACT Plants of the Cannabis genus are the only prolific producers of phytocannabinoids, compounds that strongly interact with the evolutionarily ancient endocannabinoid receptors shared by most bilaterian taxa. For millennia, the plant has been cultivated not only for these compounds, but also for food, rope, paper, and clothing. Today, specialized varieties yielding high-quality textile fibers, nutritional seed oil, or high cannabinoid [...]

Lire la suite

On the Relationship between Classic Psychedelics and Suicidality : A Systematic Review, Richard J. Zeifman et al., 2021

On the Relationship between Classic Psychedelics and Suicidality : A Systematic Review Richard J. Zeifman, Nikhita Singhal, Leah Breslow, & Cory R. Weissman ACS Pharmacology & Translational Science, 2021, 4, (2), 436-451 Doi : 10.1021/acsptsci.1c00024 Abstract Use of classic psychedelics (e.g., psilocybin, ayahuasca, lysergic acid diethylamide) is increasing and psychedelic therapy is receiving growing attention as a novel mental health intervention. Suicidality remains a potential safety concern associated with classic psychedelics and is, concurrently, a mental health concern that psychedelic therapy may show promise in targeting. Accordingly, further understanding of the relationship between classic psychedelics and suicidality is needed. Therefore, we conducted a systematic review [...]

Lire la suite

Assessing the risk-benefit profile of classical psychedelics : a clinical review of second-wave psychedelic research, David Bender & David J. Hellerstein, 2022.

Assessing the risk-benefit profile of classical psychedelics : a clinical review of second-wave psychedelic research David Bender & David J. Hellerstein Psychopharmacology (Berl), 2022. Doi : 10.1007/s00213-021-06049-6 Abstract Rationale : A broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use. Objectives : To use recently published data to assess potential risks and benefits of psychedelic drugs as therapeutics, as well as to synthesize what is currently known in order [...]

Lire la suite

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants, Felix Müller et al., 2022

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants Felix Müller, Elias Kraus, Friederike Holze, Anna Becker, Laura Ley, Yasmin Schmid, Patrick Vizeli, Matthias E. Liechti, Stefan Borgwardt Psychopharmacology, 2022, 1-11. doi : 10.1007/s00213-022-06066-z   Abstract Background : LSD and psilocybin are increasingly used in phase I trials and evaluated as therapeutic agents for mental disorders. The phenomenon of reoccurring drug-like experiences after the acute substance effects have worn off was described for both substances and especially attributed to LSD. According to the DSM-V, the persisting and distressing manifestation of these experiences is called hallucinogen-persisting perception disorder (HPPD). Data on both conditions [...]

Lire la suite

Serotonin and brain function : a tale of two receptors, RL Carhart-Harris and DJ Nutt, 2017

Serotonin and brain function : a tale of two receptors RL Carhart-Harris and DJ Nutt Journal of Psychopharmacology, 2017, Vol. 31, (9), 1091–1120. Doi : 10.1177/0269881117725915   Abstract Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data to create a novel bipartite model centred on the view that serotonin neurotransmission enhances two distinct adaptive responses to adversity, mediated in large part by its two most prevalent and researched brain receptors: the 5-HT1A and 5-HT2A receptors. We propose that passive coping (i.e. tolerating a source of stress) [...]

Lire la suite

Psychedelic psychiatry’s brave new world, Nutt, D., Erritzoe, D., & Carhart-Harris, R., 2020

Psychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020   After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.   Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]

Lire la suite